Back to Search Start Over

Role of Oxidative Stress in Hypersensitivity Reactions to Sulfonamides.

Authors :
Elzagallaai AA
Sultan EA
Bend JR
Abuzgaia AM
Loubani E
Rieder MJ
Source :
Journal of clinical pharmacology [J Clin Pharmacol] 2020 Mar; Vol. 60 (3), pp. 409-421. Date of Electronic Publication: 2019 Nov 10.
Publication Year :
2020

Abstract

Antimicrobial sulfonamides are important medications. However, their use is associated with major immune-mediated drug hypersensitivity reactions with a rate that ranges from 3% to 4% in the general population. The pathophysiology of sulfa-induced drug hypersensitivity reactions is not well understood, but accumulation of reactive metabolites (sulfamethoxazole [SMX] hydroxylamine [SMX-HA] and SMX N-nitrosamine [SMX-NO]) is thought to be a major factor. These reactive metabolites contribute to the formation of reactive oxygen species (ROS) known to cause cellular damage and induce cell death through apoptosis and necroptosis. ROS can also serve as "danger signals," priming immune cells to mount an immunological reaction. We recruited 26 sulfa-hypersensitive (HS) patients, 19 healthy control subjects, and 6 sulfa-tolerant patients to this study. Peripheral blood monocytes and platelets were isolated from blood samples and analyzed for in vitro cytotoxicity, ROS and carbonyl protein formation, lipid peroxidation, and GSH (glutathione) content after challenge with SMX-HA. When challenged with SMX-HA, cells isolated from sulfa-HS patients exhibited significantly (P ≤ .05) higher cell death, ROS and carbonyl protein formation, and lipid peroxidation. In addition, there was a high correlation between cell death in PBMCs and ROS levels. There was also depletion of GSH and lower GSH/GSSG ratios in peripheral blood mononuclear cells from sulfa-HS patients. The amount of ROS formed was negatively correlated with intracellular GSH content. The data demonstrate a major role for oxidative stress in in vitro cytotoxicity of SMX reactive metabolites and indicate increased vulnerability of cells from sulfa-HS patients to the in vitro challenge.<br /> (© 2019, The American College of Clinical Pharmacology.)

Details

Language :
English
ISSN :
1552-4604
Volume :
60
Issue :
3
Database :
MEDLINE
Journal :
Journal of clinical pharmacology
Publication Type :
Academic Journal
Accession number :
31709574
Full Text :
https://doi.org/10.1002/jcph.1535